Multimodality therapy is preferable for most subsets of patients with stage III lung cancer, with combined chemoradiotherapy leading to better survival than radiotherapy alone.

Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Stage III lung cancer has a median survival of 9 to 34 months, with higher survival rates observed in younger Caucasian women with good performance status, adenocarcinoma, mutations, stage IIIA, and multidisciplinary-team-based diagnoses.

Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival

Stage IIIC in cervical cancer has no worse survival outcomes than stage IIIA and IIIB, with stage IIIC1 having significantly better overall survival outcomes than stage IIIA and IIIB.

Survival outcomes of 2018 FIGO stage IIIC versus stages IIIA and IIIB in cervical cancer: A systematic review with meta-analysis.

Three symptom clusters, involving fatigue, cognitive impairment, and mood problems, were identified across three phases of breast cancer experience.

Symptom Clusters in Breast Cancer Across 3 Phases of the Disease

Stage of cancer classification is based on the size of the primary tumor, involvement of lymph nodes, and potential spread to other organs in the body.

What Does My Stage of Cancer Mean?

Stage III non-small cell lung cancer management requires multidisciplinary teamwork to optimize staging and treatment, ultimately improving patient care.

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer

Stage III non-small cell lung cancer staging involves imaging, non-invasive, and invasive techniques to accurately assess tumor extent, lymph node involvement, and distant metastases, guiding treatment decisions.

The multidisciplinarity of stage III non-small cell lung cancer.

Stage III non-small cell lung cancer patients benefit from effective chemotherapy regimens combined with local therapies, improving overall survival.

Stage III Non-small Cell Lung Cancer

Multimodality therapy is preferable for stage IIIA lung cancer patients, but current randomized trial data is inconclusive, limiting definitive treatment guidelines.

Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

Stage IIIA non-small cell lung cancer patients with locoregionally advanced disease benefit most from complete resection, but surgical guidelines are not universally accepted.

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer

Immunotherapy (excluding checkpoint inhibitors) shows limited effectiveness and safety in patients with stage I to III non-small cell lung cancer treated with curative surgery or radiotherapy.

Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.

Combining tumor deposits and lymph node metastases improves the prognostic accuracy of TNM staging in stage III colon cancer patients.

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance).

The AJCC sixth edition system for colon cancer staging provides more substages, with stage IIIa colon cancer having significantly better 5-year survival than stage IIb disease, potentially reflecting current clinical practice.

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.

The International Staging System for Lung Cancer simplifies diagnosis and treatment selection, with implications for all cell types and international acceptance.

A new international staging system for lung cancer.

Surgical treatment for stage IIIa (T3 or N2) lung cancer can lead to a reasonable cure, while stage IIIb (T4 or N3) is often unresectable, and stage IV is generally incurable.

Surgical treatment for higher stage non-small cell lung cancer.

Stage IIIA non-small cell lung cancer treatment varies, with multimodality therapy being preferable for patients with diverse disease presentations and limited data on optimal treatment options.

Treatment of stage IIIA non-small cell lung cancer.

Cancer progression is influenced by mutations in cellular genes and clonal selection, with early-stage defects playing a critical role in tumor initiation and aggressive behavior of advanced cancers.

Cancer progression

Early stage colon cancer treatment consists of surgery followed by adjuvant chemotherapy, with minimally invasive surgical techniques and personalized therapy potentially improving outcomes.

Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions

This paper extends Simon's two-stage design to a three-stage design, allowing for a 10% reduction in expected sample size in phase II cancer clinical trials when the treatment is not promising and the accrual rate is slow.

Optimal three-stage designs for phase II cancer clinical trials.

In the United States, clinical staging of mediastinum is variable for cStage IIIA-cN2 lung cancer patients, with low surgery use but encouraging 5-year survival.

Management of clinical stage IIIA primary lung cancers in the National Cancer Database.

These studies suggest that stage III cancer involves multimodality therapy, multidisciplinary teamwork, and specific staging techniques to improve survival and treatment outcomes.